Myeloma Patients Europe (MPE) has developed a Q&A on COVID-19 vaccination for myeloma patients to answer some of the most frequently asked questions about the approved COVID-19 vaccines in Europe. It is available in German, Armenian, Romanian, Spanish, Macedonian, French, Slovak, Hebrew and Lithuanian. Portuguese, Danish and Finnish coming soon.
An interactive e-Learning course for health professionals.
While in most cases COVID-19 symptoms pass quickly, some people are suffering long-term effects. Visit EURORDIS’s new webpage on Long COVID to learn more about this COVID-19 infection form, whose symptoms can last for over 12 weeks.
Videos and podcasts for health workers and the public to address common questions about COVID-19 vaccines.
Nathalie Moll, Director General of EFPIA on “How can we future-proof medicines regulation in the post-COVID world?”.
As the COVID-19 vaccination programme starts to be rolled out, many young women are hesitant to accept the vaccine, citing concerns about fertility. Meanwhile, those offered the vaccine during pregnancy must decide whether they will accept, even though pregnant people were excluded from the clinical trials. Data on accidental pregnancies that occurred during the trials […]
TrialX talked to reproductive endocrinologist & virologist Dr Cindy Duke of Nevada Fertility Institute to get answers to common questions and clear the air around myths related to use of COVID-19 vaccines in women who are pregnant, breastfeeding or trying to conceive naturally/via ART, and dig deeper into why the CDC quotes “they are unlikely […]
This ESMO Webinar Series provides some important considerations about COVID-19 vaccination for patients with cancer.
To illuminate some of the recent developments pursued by leading scientists during the pandemic, the IUIS collaborated with Frontiers and launched a series of weekly scientific webinars to accelerate the development of novel diagnostics, therapeutics and vaccines. Speakers shared their insights and latest research results on Covid-19-related topics, welcoming an audience that featured more than […]